Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
published in: Lancet Oncology Commission
date of publication: 2012-10-08
main subject: phase II clinical trial, patient, multicenter clinical trial
Cites articles 29
Date
Title
Article - wd:Q44442912